Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a single centre, single arm, open-label, proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will receive Sofosbuvir (SOF) and Ledipasvir (LDV) starting at time of liver transplantation (OLT) and continues for 12 weeks. Subjects will be receive 24 week post-treatment follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

NCT03619837

Hepatitis C Transplantation Disease Transmission

COMPLETED PHASE4

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

NCT03312023

Hepatitis B

COMPLETED PHASE2

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013

HCV Coinfection Liver Disease HIV

COMPLETED PHASE4

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

NCT02868242

Hepatitis C Virus Infection

COMPLETED PHASE2

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

NCT07189377

Hepatitis B Virus (HBV) Lung Transplant Recipient

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis C viral infection (HCV) leading to end-stage liver disease is the leading indication for liver transplant worldwide. HCV recurrence following liver transplantation is universal, associated with 100-fold increase in viremia levels, and runs at an accelerated course, leading to graft cirrhosis in up to 30% of patients within 5 years. Successful eradication of HCV post transplant normalizes the long term survival of HCV positive liver transplant recipients. This study aims to treat HCV infection starting at the time of transplant. The study is a single centre, single arm, open-label,proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will receive Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet starting at time of liver transplantation (OLT) and continues for 12 weeks. Subjects will receive 24 week post-treatment follow up. The study will investigate if the patient has achieved sustained virological response (SVR) 12 weeks after cessation of treatment (SVR12). Furthermore, safety and efficacy of this treatment regimen beginning at the time of transplant will be investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Viral Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SOF and LDV

Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.

Group Type EXPERIMENTAL

Sofosbuvir (SOF) and Ledipasvir (LDV)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sofosbuvir (SOF) and Ledipasvir (LDV)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Recipient of a first (primary) live or deceased (after brain or cardiac death) donor liver transplant
* Willing and able to provide written informed consent
* Male or Female, age 18-70 years old
* Medical MELD score ≤30 at time of transplant (calculated based on serum bilirubin, creatinine and INR, i.e. not taking exception points into account)
* Quantifiable HCV RNA at time of listing or transplant evaluation
* HCV genotype 1a or 1b infection
* Female patients must have a negative pregnancy test at enrolment

Exclusion Criteria

* Liver re-transplantation
* Recipients of multiple solid organ transplants
* Estimated GFR \<30ml/min at time of transplant
* Participants transplanted for fulminant hepatic failure
* Participants co-infected with HBV or HIV
* Previous treatment with a Sofosbuvir or Ledipasvir containing regimen
* Participation in an interventional clinical trial within 1 month prior to enrolment
* Known allergies or hypersensitivity to Sofosbuvir or Ledipasvir
* Pregnancy and/or lactation

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No